Document is current
Any future updates will be listed below
-
Authors
Agathangelidis, Andreas
Chatzidimitriou, Anastasia
Chatzikonstantinou, Thomas https://orcid.org/0000-0003-4105-1253
Tresoldi, Cristina https://orcid.org/0000-0001-7711-5621
Davis, Zadie
Giudicelli, Véronique
Kossida, Sofia https://orcid.org/0000-0003-2482-0022
Belessi, Chrysoula
Rosenquist, Richard
Ghia, Paolo https://orcid.org/0000-0003-3750-7342
Langerak, Anton W. https://orcid.org/0000-0002-2078-3220
Davi, Frédéric
Stamatopoulos, Kostas
,
-
Funding
Funding for this research was provided by:
General Secretariat for Research and Technology (336)
EC | Horizon 2020 Framework Programme (643638, 643638, 643638)
Svenska Forskningsrådet Formas
Cancerfonden
Knut och Alice Wallenbergs Stiftelse
Radiumhemmets Forskningsfonder
Associazione Angela Serra per la Ricerca sul Cancro (21198)
- License Information
-
More Information
Article History
Received: 6 February 2022
Revised: 4 May 2022
Accepted: 12 May 2022
First Online: 25 May 2022
Competing interests
: KS has received research support from Janssen, Abbvie, and AstraZeneca. AWL has received research support from Janssen, Gilead and Roche. RR has received honoraria from Abbvie, AstraZeneca, Janssen, Illumina, and Roche. PG has received honoraria rom AbbVie, ArQule/MSD, AstraZeneca, BeiGene, Celgene/Juno/BMS, Janssen, Lilly/Loxo, MEI, Roche, Sanofi, and research support from AbbVie, AstraZeneca, Janssen, Sunesis. FD has received honoraria from Janssen and Gilead.
